Report Detail

Medical Devices & Consumables Global Methicillin-Susceptible Staphylococcus Aureus Market Size, Status and Forecast 2021-2027

  • RnM4284551
  • |
  • 08 February, 2021
  • |
  • Global
  • |
  • 93 Pages
  • |
  • QYResearch
  • |
  • Medical Devices & Consumables

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Size Growth Rate by Treatment: 2016 VS 2021 VS 2027
    • 1.2.2 Cephalosporins
    • 1.2.3 Vancomycin
    • 1.2.4 Linezolid
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Share by End Users: 2016 VS 2021 VS 2027
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Perspective (2016-2027)
  • 2.2 Methicillin-Susceptible Staphylococcus Aureus Growth Trends by Regions
    • 2.2.1 Methicillin-Susceptible Staphylococcus Aureus Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Methicillin-Susceptible Staphylococcus Aureus Historic Market Share by Regions (2016-2021)
    • 2.2.3 Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by Regions (2022-2027)
  • 2.3 Methicillin-Susceptible Staphylococcus Aureus Industry Dynamic
    • 2.3.1 Methicillin-Susceptible Staphylococcus Aureus Market Trends
    • 2.3.2 Methicillin-Susceptible Staphylococcus Aureus Market Drivers
    • 2.3.3 Methicillin-Susceptible Staphylococcus Aureus Market Challenges
    • 2.3.4 Methicillin-Susceptible Staphylococcus Aureus Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Methicillin-Susceptible Staphylococcus Aureus Players by Revenue
    • 3.1.1 Global Top Methicillin-Susceptible Staphylococcus Aureus Players by Revenue (2016-2021)
    • 3.1.2 Global Methicillin-Susceptible Staphylococcus Aureus Revenue Market Share by Players (2016-2021)
  • 3.2 Global Methicillin-Susceptible Staphylococcus Aureus Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Methicillin-Susceptible Staphylococcus Aureus Revenue
  • 3.4 Global Methicillin-Susceptible Staphylococcus Aureus Market Concentration Ratio
    • 3.4.1 Global Methicillin-Susceptible Staphylococcus Aureus Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Methicillin-Susceptible Staphylococcus Aureus Revenue in 2020
  • 3.5 Methicillin-Susceptible Staphylococcus Aureus Key Players Head office and Area Served
  • 3.6 Key Players Methicillin-Susceptible Staphylococcus Aureus Product Solution and Service
  • 3.7 Date of Enter into Methicillin-Susceptible Staphylococcus Aureus Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Methicillin-Susceptible Staphylococcus Aureus Breakdown Data by Treatment

  • 4.1 Global Methicillin-Susceptible Staphylococcus Aureus Historic Market Size by Treatment (2016-2021)
  • 4.2 Global Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by Treatment (2022-2027)

5 Methicillin-Susceptible Staphylococcus Aureus Breakdown Data by End Users

  • 5.1 Global Methicillin-Susceptible Staphylococcus Aureus Historic Market Size by End Users (2016-2021)
  • 5.2 Global Methicillin-Susceptible Staphylococcus Aureus Forecasted Market Size by End Users (2022-2027)

6 North America

  • 6.1 North America Methicillin-Susceptible Staphylococcus Aureus Market Size (2016-2027)
  • 6.2 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment
    • 6.2.1 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2021)
    • 6.2.2 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2022-2027)
    • 6.2.3 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2027)
  • 6.3 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users
    • 6.3.1 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2021)
    • 6.3.2 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2022-2027)
    • 6.3.3 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2027)
  • 6.4 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country
    • 6.4.1 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2016-2021)
    • 6.4.2 North America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size (2016-2027)
  • 7.2 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment
    • 7.2.1 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2021)
    • 7.2.2 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2022-2027)
    • 7.2.3 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2027)
  • 7.3 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users
    • 7.3.1 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2021)
    • 7.3.2 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2022-2027)
    • 7.3.3 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2027)
  • 7.4 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Country
    • 7.4.1 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2016-2021)
    • 7.4.2 Europe Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size (2016-2027)
  • 8.2 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment
    • 8.2.1 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2021)
    • 8.2.2 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2022-2027)
    • 8.2.3 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2027)
  • 8.3 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users
    • 8.3.1 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2021)
    • 8.3.2 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2022-2027)
    • 8.3.3 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2027)
  • 8.4 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Region
    • 8.4.1 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Methicillin-Susceptible Staphylococcus Aureus Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size (2016-2027)
  • 9.2 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment
    • 9.2.1 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2021)
    • 9.2.2 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2022-2027)
    • 9.2.3 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2027)
  • 9.3 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users
    • 9.3.1 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2021)
    • 9.3.2 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2022-2027)
    • 9.3.3 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2027)
  • 9.4 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country
    • 9.4.1 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2016-2021)
    • 9.4.2 Latin America Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size (2016-2027)
  • 10.2 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment
    • 10.2.1 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2021)
    • 10.2.2 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2022-2027)
    • 10.2.3 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Treatment (2016-2027)
  • 10.3 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users
    • 10.3.1 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2021)
    • 10.3.2 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2022-2027)
    • 10.3.3 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by End Users (2016-2027)
  • 10.4 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Country
    • 10.4.1 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Methicillin-Susceptible Staphylococcus Aureus Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Dainippon Sumitomo Pharma Co., Ltd
    • 11.1.1 Dainippon Sumitomo Pharma Co., Ltd Company Details
    • 11.1.2 Dainippon Sumitomo Pharma Co., Ltd Business Overview
    • 11.1.3 Dainippon Sumitomo Pharma Co., Ltd Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.1.4 Dainippon Sumitomo Pharma Co., Ltd Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.1.5 Dainippon Sumitomo Pharma Co., Ltd Recent Development
  • 11.2 Immtech Pharmaceuticals, Inc.
    • 11.2.1 Immtech Pharmaceuticals, Inc. Company Details
    • 11.2.2 Immtech Pharmaceuticals, Inc. Business Overview
    • 11.2.3 Immtech Pharmaceuticals, Inc. Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.2.4 Immtech Pharmaceuticals, Inc. Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.2.5 Immtech Pharmaceuticals, Inc. Recent Development
  • 11.3 Lytix Biopharma AS
    • 11.3.1 Lytix Biopharma AS Company Details
    • 11.3.2 Lytix Biopharma AS Business Overview
    • 11.3.3 Lytix Biopharma AS Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.3.4 Lytix Biopharma AS Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.3.5 Lytix Biopharma AS Recent Development
  • 11.4 PharmaIN Corporation
    • 11.4.1 PharmaIN Corporation Company Details
    • 11.4.2 PharmaIN Corporation Business Overview
    • 11.4.3 PharmaIN Corporation Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.4.4 PharmaIN Corporation Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.4.5 PharmaIN Corporation Recent Development
  • 11.5 Cubist Pharmaceuticals
    • 11.5.1 Cubist Pharmaceuticals Company Details
    • 11.5.2 Cubist Pharmaceuticals Business Overview
    • 11.5.3 Cubist Pharmaceuticals Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.5.4 Cubist Pharmaceuticals Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.5.5 Cubist Pharmaceuticals Recent Development
  • 11.6 Kenta Biotech AG
    • 11.6.1 Kenta Biotech AG Company Details
    • 11.6.2 Kenta Biotech AG Business Overview
    • 11.6.3 Kenta Biotech AG Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.6.4 Kenta Biotech AG Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.6.5 Kenta Biotech AG Recent Development
  • 11.7 Arsanis Biosciences GmbH
    • 11.7.1 Arsanis Biosciences GmbH Company Details
    • 11.7.2 Arsanis Biosciences GmbH Business Overview
    • 11.7.3 Arsanis Biosciences GmbH Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.7.4 Arsanis Biosciences GmbH Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.7.5 Arsanis Biosciences GmbH Recent Development
  • 11.8 Volcano Corporation
    • 11.8.1 Volcano Corporation Company Details
    • 11.8.2 Volcano Corporation Business Overview
    • 11.8.3 Volcano Corporation Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.8.4 Volcano Corporation Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.8.5 Volcano Corporation Recent Development
  • 11.9 Abbott Laboratories
    • 11.9.1 Abbott Laboratories Company Details
    • 11.9.2 Abbott Laboratories Business Overview
    • 11.9.3 Abbott Laboratories Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.9.4 Abbott Laboratories Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.9.5 Abbott Laboratories Recent Development
  • 11.10 AngioScore Inc.
    • 11.10.1 AngioScore Inc. Company Details
    • 11.10.2 AngioScore Inc. Business Overview
    • 11.10.3 AngioScore Inc. Methicillin-Susceptible Staphylococcus Aureus Introduction
    • 11.10.4 AngioScore Inc. Revenue in Methicillin-Susceptible Staphylococcus Aureus Business (2016-2021)
    • 11.10.5 AngioScore Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Methicillin-Susceptible Staphylococcus Aureus market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Methicillin-Susceptible Staphylococcus Aureus market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment and by End Users in terms of revenue and forecast for the period 2016-2027.

    Segment by Treatment
    Cephalosporins
    Vancomycin
    Linezolid
    Others

    Segment by End Users
    Hospitals
    Clinics
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Dainippon Sumitomo Pharma Co., Ltd
    Immtech Pharmaceuticals, Inc.
    Lytix Biopharma AS
    PharmaIN Corporation
    Cubist Pharmaceuticals
    Kenta Biotech AG
    Arsanis Biosciences GmbH
    Volcano Corporation
    Abbott Laboratories
    PharmaIN Corporation


    Summary:
    Get latest Market Research Reports on Methicillin-Susceptible Staphylococcus Aureus. Industry analysis & Market Report on Methicillin-Susceptible Staphylococcus Aureus is a syndicated market report, published as Global Methicillin-Susceptible Staphylococcus Aureus Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Methicillin-Susceptible Staphylococcus Aureus market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,767.58
    4,151.37
    5,535.16
    3,208.42
    4,812.63
    6,416.83
    410,853.30
    616,279.95
    821,706.60
    282,718.41
    424,077.62
    565,436.82
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report